Gamma-aminobutyric acid type A receptor complex (GABA-A receptor)

The **Gamma-aminobutyric acid type A receptor complex** (GABA-A receptor) is a pentameric ligand-gated ion channel predominantly responsible for fast inhibitory neurotransmission in the mammalian central nervous system[1][3][10]. It is assembled from a combination of various subunits (α, β, γ, δ, etc.), each with multiple isoforms, yielding substantial structural and functional diversity[3][7][9]. The canonical receptor contains two α, two β, and one γ subunit[5][7]. When bound by GABA, the receptor opens a central chloride-permeable pore, hyperpolarizing neurons and reducing their excitability. GABA-A receptors are the target of a wide array of clinically used drugs including benzodiazepines, barbiturates, sedative-hypnotics, some anesthetics, neuroactive steroids, and certain anticonvulsants[4][6][8][10]. Mutations and dysfunctions in specific GABA-A subunits are implicated in genetic epilepsies, anxiety, sleep disturbances, and neurodevelopmental syndromes[4][9]. Pharmacological modulation can occur via agonism or allosteric modulation at various binding sites, resulting in enhancement or inhibition of receptor function. Safety issues include sedation, tolerance, physical dependence, and risk of overdose, particularly with compounds exerting strong allosteric potentiation, and in poly-drug use settings[4][10].

Other names

GABA-A receptorGABA-A receptor complexGABA\(_A\)RGamma-aminobutyric acid type A receptorGABA-activated chloride channelGABA-subtype A receptor

Positive allosteric modulation (e.g., benzodiazepines, barbiturates, neurosteroids); Agonism (e.g., muscimol, GABA); Negative allosteric modulation (e.g., DMCM, flumazenil as antagonist); Channel potentiation or inhibition